Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids

JACC Focus Seminar

Richard L. Weinberg, MD, PHD; Robert D. Brook, MD; Melvyn Rubenfire, MD; Kim A. Eagle, MD


J Am Coll Cardiol. 2021;77(5):593-608. 

In This Article

Future Directions

The reasons for the difference in findings from the REDUCE-IT trial and the STRENGTH study remain unclear. The RESPECT-EPA (Randomized trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy – Statin and Eicosapentaenoic Acid) trial is an open-label study assessing the efficacy of 1.8 g/day of EPA in Japanese adults with known coronary artery disease. The primary endpoint is a composite of CV death, nonfatal MI, nonfatal stroke, unstable angina requiring emergent hospitalization and revascularization, and coronary revascularization (Table 6).[88] This study hopefully will help clarify whether the benefits seen in the REDUCE-IT trial were primarily due to the use of pure EPA and help elucidate the optimal formulation(s) of omega-3 PUFAs for CV risk reduction. Finally, based on the secondary analyses from the VITAL trial,[17,59] it would be very interesting for future RCTs to investigate the effects of omega-3 PUFAs on CHD death and MI, with particular focus on the Black population and in populations with low intake of fatty fish.